EEF1G

Summary

EEF1G (eukaryotic translation elongation factor 1 gamma, HGNC:3213) is a protein-coding gene on chromosome 11q12.3, encoding Elongation factor 1-gamma (P26641). Probably plays a role in anchoring the complex to other cellular components. It is a common-essential gene (DepMap: required in 95.9% of cancer cell lines).

This gene encodes a subunit of the elongation factor-1 complex, which is responsible for the enzymatic delivery of aminoacyl tRNAs to the ribosome. This subunit contains an N-terminal glutathione transferase domain, which may be involved in regulating the assembly of multisubunit complexes containing this elongation factor and aminoacyl-tRNA synthetases.

Source: NCBI Gene 1937 — RefSeq curated summary.

At a glance

• GWAS associations: 12
• Clinical variants (ClinVar): 60 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• Cancer dependency (DepMap): dependent in 95.9% of screened cell lines (common-essential)
• MANE Select transcript: NM_001404

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:3213
Approved symbol	EEF1G
Name	eukaryotic translation elongation factor 1 gamma
Location	11q12.3
Locus type	gene with protein product
Status	Approved
Aliases	EF1G
Ensembl gene	ENSG00000254772
Ensembl biotype	protein_coding
OMIM	130593
Entrez	1937

Gene structure

Transcript identifiers

Ensembl transcripts: 24 — 21 protein_coding, 2 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000329251, ENST00000524420, ENST00000525340, ENST00000532986, ENST00000878312, ENST00000878313, ENST00000878314, ENST00000878315, ENST00000878316, ENST00000878317, ENST00000878318, ENST00000878319, ENST00000878320, ENST00000925053, ENST00000925054, ENST00000925055, ENST00000925056, ENST00000925057, ENST00000925058, ENST00000925059, ENST00000925060, ENST00000925061, ENST00000925062, ENST00000960087

RefSeq mRNA: 1 — MANE Select: NM_001404 NM_001404

CCDS: CCDS44626

Canonical transcript exons

ENST00000329251 — 10 exons

Exon	Start	End
ENSE00001715491	62573831	62573891
ENSE00002150889	62559596	62559837
ENSE00003465883	62560069	62560193
ENSE00003496284	62571838	62571901
ENSE00003521679	62572584	62572742
ENSE00003563564	62566806	62567010
ENSE00003568426	62560282	62560454
ENSE00003652445	62570965	62571108
ENSE00003655903	62567399	62567528
ENSE00003681596	62571540	62571682

Expression profiles

Bgee: expression breadth ubiquitous, 134 present calls, max score 99.95.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 55.0164 / max 514.1399, expressed in 1815 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
120134	44.4061	1811
120136	4.5080	1531
120138	2.6157	901
120137	1.4273	810
120135	0.9881	530
120133	0.7757	454
206314	0.1881	64
206313	0.1074	34

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cortical plate	UBERON:0005343	99.95	gold quality
ganglionic eminence	UBERON:0004023	99.92	gold quality
ventricular zone	UBERON:0003053	99.91	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	99.90	gold quality
gastrocnemius	UBERON:0001388	99.84	gold quality
muscle of leg	UBERON:0001383	99.83	gold quality
skeletal muscle tissue	UBERON:0001134	99.82	gold quality
stromal cell of endometrium	CL:0002255	99.81	gold quality
zone of skin	UBERON:0000014	99.81	gold quality
skin of abdomen	UBERON:0001416	99.81	gold quality
skin of leg	UBERON:0001511	99.81	gold quality
left ovary	UBERON:0002119	99.80	gold quality
hindlimb stylopod muscle	UBERON:0004252	99.80	gold quality
ovary	UBERON:0000992	99.79	gold quality
islet of Langerhans	UBERON:0000006	99.78	gold quality
rectum	UBERON:0001052	99.78	gold quality
right ovary	UBERON:0002118	99.78	gold quality
muscle tissue	UBERON:0002385	99.78	gold quality
fallopian tube	UBERON:0003889	99.78	gold quality
adult mammalian kidney	UBERON:0000082	99.77	gold quality
endocervix	UBERON:0000458	99.77	gold quality
smooth muscle tissue	UBERON:0001135	99.77	gold quality
prostate gland	UBERON:0002367	99.77	gold quality
ectocervix	UBERON:0012249	99.77	gold quality
lymph node	UBERON:0000029	99.76	gold quality
right uterine tube	UBERON:0001302	99.76	gold quality
uterine cervix	UBERON:0000002	99.75	gold quality
vagina	UBERON:0000996	99.75	gold quality
right lobe of thyroid gland	UBERON:0001119	99.75	gold quality
thoracic mammary gland	UBERON:0005200	99.75	gold quality

Single-cell (SCXA)

Detected in 37 experiment(s), a significant marker in 16.

Experiment	Marker?	Max mean expression
E-MTAB-6678	yes	3936.14
E-MTAB-8142	yes	131.51
E-CURD-122	yes	95.24
E-CURD-88	yes	67.75
E-CURD-46	yes	62.63
E-HCAD-11	yes	54.20
E-MTAB-9221	yes	48.66
E-MTAB-9067	yes	27.36
E-HCAD-9	yes	26.38
E-HCAD-13	yes	25.22
E-CURD-112	yes	20.33
E-ANND-3	yes	15.91
E-GEOD-135922	yes	12.11
E-MTAB-10042	yes	11.00
E-HCAD-35	yes	8.60

Regulation

Is transcription factor: no

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 95.9% of screened cell lines, common-essential.

Literature-anchored findings (GeneRIF, showing 3)

• eEF1gamma, in addition to its role in translation elongation complex, is involved in regulating Vimentin gene by contacting both pol II and the Vimentin promoter region and shuttling/nursing the Vimentin mRNA (PMID:21217813)
• Results show that eEF1Bgamma binds not only Che-1 and p53 transcripts but also their promoters. Its depletion significantly decreases p53 protein accumulation and slightly impacts on Che-1 accumulation in the mitochondria. These data support the notion that eEF1Bgamma, besides its canonical role in translation, is an RNA-binding protein and a key player in cellular stress responses. (PMID:27639846)
• study describes a novel EEF1G-ALK gene fusion in 2 pediatric patients with anaplastic large cell lymphoma that is associated with a cytoplasmic-restricted localization of the ALK fusion protein (PMID:27840423)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	eef1g	ENSDARG00000056119
mus_musculus	Eef1g	ENSMUSG00000071644
drosophila_melanogaster	eEF1gamma	FBGN0029176
caenorhabditis_elegans		WBGENE00008920

Paralogs (14): GSTO2 (ENSG00000065621), GSTT2 (ENSG00000099984), GSTZ1 (ENSG00000100577), GDAP1 (ENSG00000104381), CLIC5 (ENSG00000112782), GDAP1L1 (ENSG00000124194), GSTT2B (ENSG00000133433), GSTO1 (ENSG00000148834), CLIC2 (ENSG00000155962), CLIC6 (ENSG00000159212), CLIC4 (ENSG00000169504), CLIC3 (ENSG00000169583), CLIC1 (ENSG00000213719), GSTT4 (ENSG00000276950)

Protein

Protein identifiers

Elongation factor 1-gamma — P26641 (reviewed: P26641)

Alternative names: eEF-1B gamma

All UniProt accessions (2): P26641, Q53YD7

UniProt curated annotations — full annotation on UniProt →

Function. Probably plays a role in anchoring the complex to other cellular components.

Subunit / interactions. EF-1 is composed of four subunits: alpha, beta, delta, and gamma.

Tissue specificity. Highly expressed in pancreatic tumor tissue and to a lesser extent in normal kidney, intestine, pancreas, stomach, lung, brain, spleen and liver.

Induction. Down-regulated in response to enterovirus 71 (EV71) infection.

Isoforms (2)

UniProt ID	Names	Canonical?
P26641-1	1	yes
P26641-2	2

RefSeq proteins (1): NP_001395* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001662	EF1B_G_C	Domain
IPR004045	Glutathione_S-Trfase_N	Domain
IPR004046	GST_C	Domain
IPR010987	Glutathione-S-Trfase_C-like	Domain
IPR036249	Thioredoxin-like_sf	Homologous_superfamily
IPR036282	Glutathione-S-Trfase_C_sf	Homologous_superfamily
IPR036433	EF1B_G_C_sf	Homologous_superfamily
IPR040079	Glutathione_S-Trfase	Family
IPR050802

Pfam: PF00043, PF00647, PF02798

UniProt features (54 total): helix 24, strand 8, modified residue 6, turn 5, domain 3, cross-link 2, initiator methionine 1, chain 1, splice variant 1, sequence conflict 1, region of interest 1, compositionally biased region 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
5JPO	X-RAY DIFFRACTION	2
5DQS	X-RAY DIFFRACTION	2.1
1PBU	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P26641-F1	85.93	0.65

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (8): 401, 434, 434, 253, 285, 2, 147, 212

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-156842	Eukaryotic Translation Elongation
R-HSA-9725370	Signaling by ALK fusions and activated point mutants

MSigDB gene sets: 229 (showing top): MODULE_151, GNF2_TPT1, GCM_NPM1, MORF_UBE2I, MODULE_150, HSIAO_HOUSEKEEPING_GENES, TGACCTY_ERR1_Q2, MODULE_149, GGGTGGRR_PAX4_03, GOBP_TRANSLATION, MORF_CCNI, BLALOCK_ALZHEIMERS_DISEASE_UP, GNF2_FBL, GOBP_TRANSLATIONAL_ELONGATION, LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_DN

GO Biological Process (3): translational elongation (GO:0006414), response to virus (GO:0009615), translation (GO:0006412)

GO Molecular Function (3): translation elongation factor activity (GO:0003746), cadherin binding (GO:0045296), protein binding (GO:0005515)

GO Cellular Component (6): nucleus (GO:0005634), cytoplasm (GO:0005737), cytosol (GO:0005829), membrane (GO:0016020), extracellular exosome (GO:0070062), endoplasmic reticulum (GO:0005783)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Translation	1
Signaling by ALK in cancer	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
macromolecule biosynthetic process	2
translational elongation	2
intracellular membrane-bounded organelle	2
cytoplasm	2
translation	1
response to other organism	1
peptidyltransferase activity	1
translational initiation	1
translational termination	1
protein metabolic process	1
protein biosynthetic process	1
translation factor activity	1
cell adhesion molecule binding	1
binding	1
intracellular anatomical structure	1
extracellular vesicle	1
endomembrane system	1

Protein interactions and networks

STRING

5865 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
EEF1G	EEF1B2	P24534	999
EEF1G	EEF1D	P29692	999
EEF1G	EEF1A1	P04719	973
EEF1G	PARS2	Q7L3T8	775
EEF1G	EEF1A2	P54266	755
EEF1G	HPGDS	O60760	740
EEF1G	EEF2	P13639	713
EEF1G	EPRS1	P07814	711
EEF1G	GAPDH	P00354	705
EEF1G	OAZ1	P54368	672
EEF1G	KTN1	Q86UP2	622
EEF1G	RPL19	P14118	613
EEF1G	EEF1E1	O43324	611
EEF1G	RPS18	P25232	599
EEF1G	CCT3	P49368	592

IntAct

379 interactions, top by confidence:

A	B	Type	Score
EEF1B2	EEF1G	psi-mi:“MI:0915”(physical association)	0.890
EEF1G	EEF1D	psi-mi:“MI:0915”(physical association)	0.810
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
EEF1G	EEF1D	psi-mi:“MI:0915”(physical association)	0.670
NCBP2	KPNA3	psi-mi:“MI:0914”(association)	0.640
EEF1G	NIP1	psi-mi:“MI:0915”(physical association)	0.560
EEF1G	DSS4	psi-mi:“MI:0915”(physical association)	0.560
	EEF1G	psi-mi:“MI:0915”(physical association)	0.560
EEF1G	ASN2	psi-mi:“MI:0915”(physical association)	0.560
NIP1	EEF1G	psi-mi:“MI:0915”(physical association)	0.560
EEF1G		psi-mi:“MI:0915”(physical association)	0.560
ASN2	EEF1G	psi-mi:“MI:0915”(physical association)	0.560
DSS4	EEF1G	psi-mi:“MI:0915”(physical association)	0.560
CHEK2	PPM1G	psi-mi:“MI:0914”(association)	0.560
PKN1	EEF1G	psi-mi:“MI:0915”(physical association)	0.560
MYG1	EEF1G	psi-mi:“MI:0915”(physical association)	0.560
TYR	EEF1G	psi-mi:“MI:0915”(physical association)	0.560
EEF1G	UQCRC1	psi-mi:“MI:0915”(physical association)	0.560
BRK1	EEF1G	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (667): EEF1G (Two-hybrid), EEF1G (Two-hybrid), EEF1G (Reconstituted Complex), EEF1G (Reconstituted Complex), EEF1G (Affinity Capture-MS), EEF1G (Two-hybrid), EEF1G (Two-hybrid), ILF2 (Two-hybrid), RBM6 (Two-hybrid), KLHL18 (Two-hybrid), PLGRKT (Two-hybrid), EEF1DP3 (Two-hybrid), EEF1G (Two-hybrid), EEF1G (Affinity Capture-MS), EEF1G (Affinity Capture-MS)

ESM2 similar proteins: A0A1U8QXK4, A2Q127, O04487, O14617, O75061, P06625, P08240, P12261, P15368, P26641, P26642, P29547, P29694, P30111, P35611, P36008, P40921, P54412, P78615, Q0II26, Q13155, Q17N71, Q27974, Q29387, Q32PX2, Q3MHE8, Q3SZV3, Q4R7H5, Q4WB03, Q5RA10, Q5Z627, Q68FR6, Q6PE25, Q6YW46, Q7PZD5, Q80TZ3, Q865S1, Q8R010, Q90YC0, Q91375

Diamond homologs: A0A1U8QXK4, A0A6J4B5J2, A2Q127, C8VQ63, P0CG29, P0CG30, P12261, P26641, P26642, P29547, P29694, P36008, P40921, P42936, Q00717, Q29387, Q3SZV3, Q4R7H5, Q4WB03, Q5Z627, Q68FR6, Q6PE25, Q6YW46, Q90YC0, Q9D8N0, Q9FUM1, Q9VG98, Q9ZRI7, S0EHD0, W7MMJ0, B5BP46, O80852, P04907, P12653, P45875, P54412, P9WEZ8, Q84TK0, Q8KN33, Q91375

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
EEF1G	“form complex”	“EEF1B complex”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 172 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
PIP3 activates AKT signaling	11	6.7×	6e-04
Intracellular signaling by second messengers	8	6.6×	6e-03

GO biological processes:

GO term	Partners	Fold	FDR
tricarboxylic acid cycle	5	19.2×	2e-03
autophagosome maturation	6	15.8×	7e-04
positive regulation of fibroblast proliferation	7	15.6×	2e-04
cellular response to hydrogen peroxide	7	12.3×	7e-04
mitophagy	5	11.9×	8e-03
positive regulation of proteasomal ubiquitin-dependent protein catabolic process	6	9.5×	7e-03
negative regulation of gene expression	10	5.2×	5e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

60 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	41
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1189 predictions. Top by Δscore:

Variant	Effect	Δscore
11:62559833:CTCAG:C	acceptor_gain	1.0000
11:62559834:TCAG:T	acceptor_gain	1.0000
11:62559834:TCAGC:T	acceptor_loss	1.0000
11:62559835:CAG:C	acceptor_gain	1.0000
11:62559835:CAGC:C	acceptor_gain	1.0000
11:62559836:AG:A	acceptor_gain	1.0000
11:62559836:AGCT:A	acceptor_loss	1.0000
11:62559837:GCTG:G	acceptor_loss	1.0000
11:62559838:C:CC	acceptor_gain	1.0000
11:62559838:CTG:C	acceptor_loss	1.0000
11:62560062:T:A	donor_gain	1.0000
11:62560064:CTCAC:C	donor_loss	1.0000
11:62560065:TCACC:T	donor_loss	1.0000
11:62560066:CA:C	donor_loss	1.0000
11:62560067:A:AC	donor_gain	1.0000
11:62560068:C:CC	donor_gain	1.0000
11:62560068:C:CT	donor_loss	1.0000
11:62560068:C:T	donor_loss	1.0000
11:62560189:CATTC:C	acceptor_gain	1.0000
11:62560190:ATTC:A	acceptor_gain	1.0000
11:62560191:TTC:T	acceptor_gain	1.0000
11:62560192:TC:T	acceptor_gain	1.0000
11:62560193:CC:C	acceptor_gain	1.0000
11:62560194:C:CA	acceptor_loss	1.0000
11:62560194:C:CC	acceptor_gain	1.0000
11:62560200:C:CT	acceptor_gain	1.0000
11:62560201:G:T	acceptor_gain	1.0000
11:62560203:C:CT	acceptor_gain	1.0000
11:62560276:TCTTA:T	donor_loss	1.0000
11:62560277:CTTA:C	donor_loss	1.0000

AlphaMissense

2884 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:62560101:A:G	W375R	1.000
11:62560101:A:T	W375R	1.000
11:62560106:C:T	G373E	1.000
11:62560193:C:T	G344E	1.000
11:62560290:A:G	L341P	1.000
11:62560430:C:A	K294N	1.000
11:62560430:C:G	K294N	1.000
11:62560432:T:C	K294E	1.000
11:62559682:C:A	K437N	0.999
11:62559682:C:G	K437N	0.999
11:62559695:C:T	G433D	0.999
11:62559696:C:G	G433R	0.999
11:62559798:A:G	W399R	0.999
11:62559798:A:T	W399R	0.999
11:62559816:C:G	D393H	0.999
11:62560107:C:G	G373R	0.999
11:62560107:C:T	G373R	0.999
11:62560147:A:C	S359R	0.999
11:62560147:A:T	S359R	0.999
11:62560149:T:G	S359R	0.999
11:62560151:G:T	A358D	0.999
11:62560153:G:C	F357L	0.999
11:62560153:G:T	F357L	0.999
11:62560155:A:G	F357L	0.999
11:62560164:T:C	K354E	0.999
11:62560166:C:A	R353M	0.999
11:62560178:A:G	L349P	0.999
11:62560181:C:G	R348P	0.999
11:62560282:C:G	G344R	0.999
11:62560282:C:T	G344R	0.999

dbSNP variants (sampled 300 via entrez): RS1000147208 (11:62568791 G>A), RS1000451807 (11:62567325 G>A,T), RS1000630294 (11:62571239 C>A,T), RS1000736984 (11:62562295 G>A), RS1001006923 (11:62560601 A>C), RS1001061820 (11:62573470 C>A), RS1001090242 (11:62567094 A>C,G), RS1001367866 (11:62570345 A>T), RS1001419989 (11:62570189 G>C), RS1001485504 (11:62573975 T>A,C), RS1001643910 (11:62568099 G>C), RS1001925456 (11:62565722 A>G), RS1002074966 (11:62568464 A>G), RS1002101642 (11:62559991 T>A,G), RS1002382551 (11:62566612 C>G)

Disease associations

OMIM: gene MIM:130593 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

12 associations (top):

Study	Trait	p-value
GCST004567_101	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction)	8.000000e-08
GCST004567_28	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction)	1.000000e-07
GCST004567_9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction)	5.000000e-07
GCST004567_90	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction)	1.000000e-07
GCST004576_22	Waist-to-hip ratio adjusted for body mass index	4.000000e-08
GCST004576_24	Waist-to-hip ratio adjusted for body mass index	5.000000e-08
GCST004576_48	Waist-to-hip ratio adjusted for body mass index	3.000000e-08
GCST004576_50	Waist-to-hip ratio adjusted for body mass index	9.000000e-07
GCST004578_41	Waist-to-hip ratio adjusted for BMI in active individuals	3.000000e-06
GCST004578_79	Waist-to-hip ratio adjusted for BMI in active individuals	3.000000e-06
GCST005956_12	Waist-to-hip ratio adjusted for BMI	2.000000e-06
GCST005962_37	Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test)	5.000000e-07

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0007788	BMI-adjusted waist-hip ratio
EFO:0008002	physical activity measurement
EFO:0008007	age at assessment
EFO:0008343	sex interaction measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4295735 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,538 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1232461	MOLIBRESIB	2	1,538

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

5 potent at pChembl≥5 of 5 total, top 5 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.31	Kd	0.491	nM	CHEMBL5653589
9.31	ED50	0.491	nM	CHEMBL5653589
7.94	Kd	11.42	nM	CHEMBL3752910
7.94	ED50	11.42	nM	CHEMBL3752910
5.37	IC50	4300	nM	MOLIBRESIB

PubChem BioAssay actives

3 with measured affinity, of 12 total; 3 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148288: Binding affinity to human EEF1G incubated for 45 mins by Kinobead based pull down assay	kd	0.0005	uM
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148288: Binding affinity to human EEF1G incubated for 45 mins by Kinobead based pull down assay	kd	0.0114	uM
2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide	2178856: Inhibition of EEF1G (unknown origin) incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	ic50	4.3000	uM

CTD chemical–gene interactions

59 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases expression, decreases methylation	4
perfluorooctanoic acid	decreases expression, increases expression	2
perfluorooctane sulfonic acid	increases expression, decreases expression	2
chloropicrin	affects expression, decreases expression	2
Tobacco Smoke Pollution	affects expression, increases metabolic processing	2
aristolochic acid I	increases expression	1
FR900359	decreases phosphorylation	1
TAK-243	decreases sumoylation	1
perfluorodecanesulfonic acid	increases expression	1
uranyl acetate	affects expression	1
titanium dioxide	decreases expression	1
pyrogallol 1,3-dimethyl ether	affects cotreatment, affects localization, decreases expression	1
beta-lapachone	increases expression	1
arsenite	increases reaction, affects binding	1
3,3’-diindolylmethane	increases expression, increases reaction	1
sodium arsenite	decreases expression	1
cobaltous chloride	increases expression	1
quinoline	increases expression	1
perfluoro-n-nonanoic acid	decreases expression	1
tanespimycin	decreases expression, affects cotreatment	1
fenpyroximate	decreases expression	1
perfluorohexanesulfonic acid	decreases expression	1
nutlin 3	affects cotreatment, increases secretion	1
STA 9090	decreases expression	1
bisphenol S	increases expression	1
VER 155008	affects cotreatment, decreases expression	1
bisphenol AF	increases expression	1
Temozolomide	decreases expression	1
Arsenic Trioxide	decreases expression	1
Arsenic	affects methylation	1

ChEMBL screening assays

9 unique, capped per target: 9 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4119049	Binding	Binding affinity to EEF1G in human NCI-H358 cells at 1 uM by mass spectrometry based pull down assay	Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. — Bioorg Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.